Evolus has posted record quarterly sales thanks to a surge in sales of its botulinum toxin Nabota. The company generated USD 126 million in sales in the first half of the year, lighting a green light to achieving its performance target for the year. Evolus plans to continue to grow sales by expanding Nabota's international approvals and launching new filler products to market.

According to industry sources on the 2nd, Evolus' revenue in Q2 this year was USD 66.9 million (KRW 92 billion), up 35.6% from the USD 49.35 million it had made in the same period a year ago.

Most of Evolus' revenue came from sales of Nabota (U.S. brand name: Jeuveau). Daewoong Pharmaceutical signed a supply